Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616 · View on ClinicalTrials.gov ↗
Study Summary
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Brentuximab vedotin
- DRUG Vinblastine
- RADIATION Involved site radiotherapy
- DRUG Bleomycin
Study Locations (20)
Other
- Royal Adelaide Hospital — Adelaide
- Box Hill Hospital — Box Hill
- Royal Brisbane and Women's Hospital — Brisbane
- Royal Darwin Hospital — Darwin
- Liverpool Hospital — Liverpool
- Sunshine Hospital (Western Health) — Melbourne
- Concord Repatriation General Hospital — Sydney
- St George Hospital — Sydney
- Universitair Ziekenhuis Antwerpen — Antwerp
- Ziekenhuis Netwerk Antwerpen — Antwerp
- UZ Leuven — Leuven
- CHU-UCL Namur — Namur
California
- Stanford University - (Stanford Cancer Institute) — Stanford
Florida
- University of Miami School of Medicine — Miami
New York
- Memorial Sloan Kettering Cancer Center — New York
New South Wales
- Royal North Shore Hospital — Saint Leonards
Queensland
- Townsville University Hospital — Townsville
West Flanders
- AZ Delta Campus Rumbeke — Roeselare
Nova Scotia
- QEII Health Sciences Centre — Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,042 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2032-09 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04685616
The ClinicalTrials.gov registry entry for NCT04685616 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,042 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University College, London, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions — of which Doxorubicin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04685616 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Other, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04685616 about?
NCT04685616 is a clinical study titled "Brentuximab Vedotin in Early Stage Hodgkin Lymphoma". RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials G...
What is the current status of trial NCT04685616?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,042 participants. The study started on 2022-04-14. Estimated completion is 2032-09.
What conditions does trial NCT04685616 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04685616?
The interventions under investigation include: Doxorubicin (DRUG), Brentuximab vedotin (DRUG), Vinblastine (DRUG), Involved site radiotherapy (RADIATION), Bleomycin (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04685616?
This trial is sponsored by University College, London, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04685616 being conducted?
This trial has 20 study locations across California, Florida, New York, New South Wales, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.